

| 货号 | ARO-A10014 |
|---|---|
| 品牌 | ProteoGenix |
| 描述 |
Anti-Human MET/c-Met/HGFR Antibody (224G11), PerCP [224G11] (ARO-A10014) is a human monoclonal antibody detecting Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET in FCM. Suitable for Human.
Highlights
|
| 种属反应性 | Human |
| 应用 | FCM |
| 宿主 | Human |
| 同种型 | IgG1, kappa |
| 克隆号 | 224G11 |
| 偶联物 | PerCP |
| 克隆类型 | Monoclonal |
| 靶标 | Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET |
| 内毒素水平 | Please contact with the lab for this information. |
| Accession号 | P08581 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| 稳定性和存储 | Store at 4°C for 12 months. Protect from light. Do not freeze. |
| 背景 | Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant). |
| Note | For research use only. |

24小时产品查询

扫一扫关注我们

专属渠道经理